Zhuzhou Qianjin Pharmaceutical Co., Ltd.SSE: 600479

Announcement on Outline of the Q3 2025 Performance Briefing

· Issued by Zhuzhou Qianjin Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · · 4 pages · Chinese

Summary by 6ix AI

The company addressed various investor inquiries regarding its operational results and financial status during the briefing. Key topics included the expansion of new product production lines, the impact of rising costs on profits, and the company's future growth strategies. The company confirmed its commitment to maintaining stable dividends and discussed its digital transformation efforts in the pharmacy sector.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

Zhuzhou Qianjin Pharmaceutical Co., Ltd. on 6ix

Earlier from Zhuzhou Qianjin Pharmaceutical

Later from Zhuzhou Qianjin Pharmaceutical

All Zhuzhou Qianjin Pharmaceutical news releases